The Latest Breaking News from FDA

Alzheimer’s disease is the most prevalent form of dementia and, with a rapidly ageing global population, it is fuelling unprecedented demand for costly patient care. There have been an estimated 400 clinical studies since the first Alzheimer’s drug trial in 1987.

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00 per share.

Avoiding unseen food hazards is the reason people often check the dates on food packaging.

The FDA has effectively thrown up its hands over its most important food-related role.

Though doctors and advocates have helped speed up access to the antiviral pills – of which the U.S. has enough to treat 1.7 million people – health providers are few and forms are still required.

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Here's a roundup of top developments in the biotech space over the last 24 hours:

CHARLOTTE, N.C. — As COVID-19 cases soar around the country, fake treatments continue to linger on the open market, posing a safety risk to those seeking medical care.